Evaluating the Role of Ki-67 Expression as a Predictor of Pathological Response to Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

By
Yongliang Niu
Junguo Li
Bowen Ding
Haitang Yang
Hui Zhao
Diming Wang
July 7, 2026

Frontiers In Oncology

1

The study analyzed 137 patients with stage IIIA–IIIB lung squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy.
2

A major pathological response (MPR) and pathological complete response (pCR) rate of 56.2% was achieved among the patients.
3

Ki-67 expression at an optimal cutoff of 55% was identified as a significant predictor of MPR/pCR in the study.
4

High Ki-67 (≥55%) correlated with a higher MPR/pCR rate compared to low Ki-67 (69.6% vs. 27.9%, P<0.001).
5

Smoking status was also found to be an independent predictor of MPR/pCR alongside Ki-67 expression.

Original Source(s)

Frontiers In Oncology

Predictive value of Ki-67 expression in predicting pathological response to neoadjuvant chemotherapy combined with immunotherapy in lung squamous cell carcinoma

by Yongliang Niu, Junguo Li, Bowen Ding, Haitang Yang, Hui Zhao, Diming Wang
July 7, 2026

Related Content

Jama Network Open

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

Nature Medicine

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Dana-Farber

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

by
August 26, 2026
5 min